As of 2026-10-02, the Intrinsic Value of Immunovant Inc (IMVT) is -13.04 USD. This IMVT valuation is based on the model Peter Lynch Fair Value. With the current market price of 33.65 USD, the upside of Immunovant Inc is -138.75%.
Based on its market price of 33.65 USD and our intrinsic valuation, Immunovant Inc (IMVT) is overvalued by 138.75%.
Note: result may not be accurate due to the invalid valuation result of Peter Lynch's fair value model.
| Range | Selected | Upside | |
| a | |||
| Fair Value | -13.04 - -13.04 | -13.04 | -138.75% |
| P/E | (65.97) - (76.14) | (71.38) | -312.1% |
| DDM - Stable | (15.52) - (47.22) | (31.37) | -193.2% |
| DDM - Multi | (3.85) - (9.53) | (5.53) | -116.4% |
| Market Cap (mil) | 6,945.36 |
| Beta | 1.26 |
| Outstanding shares (mil) | 206.40 |
| Enterprise Value (mil) | 6,147.56 |
| Market risk premium | 4.60% |
| Cost of Equity | 12.36% |
| Cost of Debt | 5.00% |
| WACC | 8.68% |